Creating a strong patent portfolio through constant communication
Why patenting should not stop at the drug candidate stage – and why coordination between researchers and attorneys is essential for strong protection
Read More
Aug 21, 2026 | Intelligence
Why patenting should not stop at the drug candidate stage – and why coordination between researchers and attorneys is essential for strong protection
Read MoreAug 20, 2026 | Intelligence
Strengthening strategic judgement during uncertainty – exploring the strategic concepts that matter most
Read MoreAug 19, 2026 | Intelligence
Amazon’s entry into the GLP-1 market should be a signal to pharma that it needs to shift focus from molecule to ‘Operating Model’
Read MoreAug 18, 2026 | Intelligence
Precision medicine is no longer theoretical, but increasingly achievable for people living with lupus
Read MoreJul 31, 2026 | Intelligence
A spark of creativity can cut through complexity, adding real value and helping to forge true connections with patients
Read MoreJul 8, 2026 | Intelligence
The UK’s challenge is less about capability and more about how well it aligns with the way global pharma now operates
Read MoreJul 7, 2026 | Intelligence
Making launch more effective, precise, cost-effective and agile demands new thinking and new technologies
Read MoreJul 6, 2026 | Intelligence
Translating emerging science into care that works meaningfully in practice
Read MoreJun 30, 2026 | Intelligence
Industry needs to press the accelerator to adopt AI across functions to
supercharge launch excellence
Jun 16, 2026 | Intelligence
Aligning policy and public funding strategies to support brain health across Europe
Read MoreJun 12, 2026 | Intelligence
The WHO classified obesity as a chronic disease over twenty years ago – but UK policy has yet to follow
Read MoreJun 10, 2026 | Intelligence
As GLP-1s redefine the treatment landscape for obesity, they are also promising candidates to influence a wide range of disease pathways
Read More
